Mesoblast (MESO) - 2026 Q2 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenues for the first half of FY 2026 were $51.3 million, driven by the successful launch of Ryoncil, with net product revenues of $49 million and a gross margin of 93% [9][10] - R&D expenses increased to $46.1 million from $5.1 million in the prior year, primarily due to trials and preparations for BLA [9][10] - Sales and general administrative expenses rose to $28.5 million from $18 million, reflecting increased sales and marketing efforts [10] - The net loss for the period was $40.2 million, down from $48 million in the prior year [10][11] - Cash at the end of December 2025 was $130 million, with a new $125 million non-dilutive credit line facility established [12][13] Business Line Data and Key Metrics Changes - Ryoncil, the first FDA-approved allogeneic mesenchymal stromal cell product, generated $49 million in net revenue in the first half of FY 2026 [7][9] - The company aims to achieve a 20% market share for Ryoncil in the pediatric population by the end of the fiscal year [19][56] Market Data and Key Metrics Changes - Ryoncil is now covered by insurance plans representing over 280 million lives, with Medicaid coverage in all states [22] - The product has been included in the formularies of 30 treatment centers, facilitating its adoption [20] Company Strategy and Development Direction - The company plans to expand Ryoncil's label indications and seek approval for Revascor and Ryoncil products, focusing on cash flow and operational efficiency [5][6] - Strategic priorities include identifying appropriate patients for Ryoncil therapy, reinforcing patient outcomes, and empowering caregivers [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year Ryoncil net revenues between $110 million and $120 million [15][49] - The company is focused on building infrastructure to support Ryoncil's market potential and is optimistic about the upcoming BLA filing for Revascor [46][44] Other Important Information - The company is evaluating multiple indications for its second-generation platform, rexlemestrocel-L, targeting chronic discogenic low back pain and chronic ischemic heart failure [29][30] - The company has received positive feedback from the FDA regarding the potential filing of a BLA based on ongoing trials [30][83] Q&A Session Summary Question: Guidance for the upcoming year - The company projects full fiscal year net revenues ranging from $110 million to $120 million [53] Question: Ryoncil penetration in pediatrics - The company aims for a 20% penetration in the pediatric population by the end of the fiscal year, based on a patient range of 300 to 375 [56][57] Question: Revascor BLA and FDA input - The company plans to seek a label for the entire patient population, emphasizing the efficacy of Revascor across all patients [62] Question: Chronic back pain data submission - The ongoing phase III trial will be the primary dataset for the BLA submission, with previous trials serving as supportive data [66][70] Question: FDA confirmation on chronic lower back pain endpoint - The company has received confirmation from the FDA that the 12-month pain endpoint is sufficient for approval [83]